Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00057720 · ClinicalTrials.gov registry record · Phase 3
TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer
A Phase 3 study, sponsored by Telik.
- Completed
- Registry status
- Phase 3
- Development phase
- 440
- Enrollment target
NCT00057720: Completed Phase 3 study, sponsored by Telik.
NCT00057720 is a Phase 3 study that has completed, run by Telik. The registered enrollment target is 440 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (43% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00057720, a Phase 3 study, has completed, sponsored by Telik.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 440 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate superiority in survival in favor of TLK286 as compared to active control therapy with Doxil/Caelyx or Hycamtin in the intent-to-treat (ITT) populations.
Interventions
- DRUG TLK286 HCl for injection
- DRUG topotecan hydrochloride for injection
- DRUG doxorubicin HCl liposome injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 440 participants |
| Start Date | 2003-06 |
| Est. Completion | 2006-12 |
| Phase | Phase 3 |
What the finished NCT00057720 record still lists
NCT00057720 is an interventional study that assigns participants to a tested intervention. The registered 440 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (43% lower).
The record links to 0 conditions, and to 3 interventions - of which TLK286 HCl for injection is the first listed.
NCT00057720 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00057720 about?
NCT00057720 is a clinical study titled "TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer". The purpose of this study is to demonstrate superiority in survival in favor of TLK286 as compared to active control therapy with Doxil/Caelyx or Hycamtin in the intent-to-treat (ITT) populations.
What is the current status of trial NCT00057720?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 440 participants. The study started on 2003-06. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00057720?
The interventions under investigation include: TLK286 HCl for injection (DRUG), topotecan hydrochloride for injection (DRUG), doxorubicin HCl liposome injection (DRUG).
Who is sponsoring clinical trial NCT00057720?
This trial is sponsored by Telik, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00057720's enrollment target sits among peer trials
440 867th of 2000 higher than 1,129 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05114538 · 440 participants · NA
Improving the Part C Early Intervention Service Delivery System for Children with ASD
- NCT05117619 · 440 participants · NA
The HOME Program for Individuals With Traumatic Brain Injury and Family Members
- NCT05602194 · 440 participants · Phase 3
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
- NCT05624879 · 440 participants · NA
Accelerated Resolution Therapy for Early Maladaptive Grief
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia